Literature DB >> 9596702

Age-dependent Neisseria meningitidis serogroup C class-specific antibody concentrations and bactericidal titers in sera from young children from Montana immunized with a licensed polysaccharide vaccine.

S E Maslanka1, J W Tappero, B D Plikaytis, R S Brumberg, J K Dykes, L L Gheesling, K B Donaldson, A Schuchat, J Pullman, M Jones, J Bushmaker, G M Carlone.   

Abstract

Neisseria meningitidis serogroup C bactericidal titers and class-specific enzyme-linked immunosorbent assay (ELISA) antibody concentrations were measured in sera from 173 children (1 to 5 years old) before and 6 weeks and 7 months following vaccination with a quadrivalent (A/C/Y/W-135) polysaccharide vaccine. The immune responses of the children were compared with those of 40 adults 6 weeks postvaccination. Both bactericidal titers and ELISA antibody concentrations were significantly higher in the adults than in the children (P < 0.05). In addition, the ratio of immunoglobulin G (IgG) to IgM was higher in the children than in the adults. With an ELISA total antibody concentration of >/=2 microg/ml used as a measure of seroconversion, >/=84% of the individuals from each age group responded to the serogroup C polysaccharide. However, with a >/=4-fold-increase in bactericidal titer used, only 18% of 1-year-olds, 32% of 2-year-olds, and 50 to 60% of 3-, 4-, and 5-year-olds seroconverted. The ELISA results suggest that >50% of all children retained >/=2 microg of total antibody per ml at 7 months postimmunization. However, the bactericidal titers suggest that <10% of children <4 years old retained a >/=4-fold increase at 7 months following vaccination. Of particular note, 59 of 79 sera (75%) from the 1- and 2-year-olds had high ELISA antibody concentrations (2 to 20 microg/ml) with no associated bactericidal titer (<1:8). Discordant results between bactericidal titers and ELISA antibody concentrations were not explained by the presence of IgA blocking antibody or relative levels of IgG and IgM. The bactericidal results show age-dependent differences in the production and retention of antibody in young children immunized with serogroup C polysaccharide; these differences are not evident with the ELISA data.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9596702      PMCID: PMC108224          DOI: 10.1128/IAI.66.6.2453-2459.1998

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  37 in total

1.  Correlation between antibody affinity and serum bactericidal activity in infants.

Authors:  S V Hetherington; M L Lepow
Journal:  J Infect Dis       Date:  1992-04       Impact factor: 5.226

Review 2.  Thymus-independent and thymus-dependent responses to polysaccharide antigens.

Authors:  K E Stein
Journal:  J Infect Dis       Date:  1992-06       Impact factor: 5.226

3.  Conjugate meningococcal serogroup A and C vaccine: reactogenicity and immunogenicity in United Kingdom infants.

Authors:  C K Fairley; N Begg; R Borrow; A J Fox; D M Jones; K Cartwright
Journal:  J Infect Dis       Date:  1996-12       Impact factor: 5.226

4.  Avidity of specific IgG antibodies elicited by immunisation against Haemophilus influenzae type b.

Authors:  A E Agbarakwe; H Griffiths; N Begg; H M Chapel
Journal:  J Clin Pathol       Date:  1995-03       Impact factor: 3.411

5.  Analysis of meningococcal serogroup C-specific antibody levels in British Columbian children and adolescents.

Authors:  L A Mitchell; J J Ochnio; C Glover; A Y Lee; M K Ho; A Bell
Journal:  J Infect Dis       Date:  1996-04       Impact factor: 5.226

6.  Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine.

Authors:  A Leach; P A Twumasi; S Kumah; W S Banya; S Jaffar; B D Forrest; D M Granoff; D E LiButti; G M Carlone; L B Pais; C V Broome; B M Greenwood
Journal:  J Infect Dis       Date:  1997-01       Impact factor: 5.226

7.  Functional differences in idiotypically defined IgG1 anti-polysaccharide antibodies elicited by vaccination with Haemophilus influenzae type B polysaccharide-protein conjugates.

Authors:  A H Lucas; D M Granoff
Journal:  J Immunol       Date:  1995-04-15       Impact factor: 5.422

8.  Assignment of Neisseria meningitidis serogroup A and C class-specific anticapsular antibody concentrations to the new standard reference serum CDC1992.

Authors:  P K Holder; S E Maslanka; L B Pais; J Dykes; B D Plikaytis; G M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  1995-03

9.  Antibody response after immunization of Brazilian children with serogroup C meningococcal polysaccharide noncovalently complexed with outer membrane proteins.

Authors:  L G Milagres; A P Lemos; C E Meles; E L Silva; L H Ferreira; J A Souza; G M Carlone
Journal:  Braz J Med Biol Res       Date:  1995-09       Impact factor: 2.590

10.  Total and functional antibody response to a quadrivalent meningococcal polysaccharide vaccine among children.

Authors:  W J King; N E MacDonald; G Wells; J Huang; U Allen; F Chan; W Ferris; F Diaz-Mitoma; F Ashton
Journal:  J Pediatr       Date:  1996-02       Impact factor: 4.406

View more
  26 in total

1.  Meningococcal group C conjugate vaccines.

Authors:  J Maclennan
Journal:  Arch Dis Child       Date:  2001-05       Impact factor: 3.791

2.  Induction of a protective capsular polysaccharide antibody response to a multiepitope DNA vaccine encoding a peptide mimic of meningococcal serogroup C capsular polysaccharide.

Authors:  Deborah M Prinz; S Louise Smithson; Thomas Kieber-Emmons; M A Julie Westerink
Journal:  Immunology       Date:  2003-10       Impact factor: 7.397

Review 3.  Correlates of protection induced by vaccination.

Authors:  Stanley A Plotkin
Journal:  Clin Vaccine Immunol       Date:  2010-05-12

4.  Importance of complement source in measuring meningococcal bactericidal titers.

Authors:  G F Santos; R R Deck; J Donnelly; W Blackwelder; D M Granoff
Journal:  Clin Diagn Lab Immunol       Date:  2001-05

5.  The effect of rituximab on vaccine responses in patients with immune thrombocytopenia.

Authors:  Ishac Nazi; John G Kelton; Mark Larché; Denis P Snider; Nancy M Heddle; Mark A Crowther; Richard J Cook; Alan T Tinmouth; Joy Mangel; Donald M Arnold
Journal:  Blood       Date:  2013-07-12       Impact factor: 22.113

6.  Vaccination responses to capsular polysaccharides of Neisseria meningitidis and Haemophilus influenzae type b in two C2-deficient sisters: alternative pathway-mediated bacterial killing and evidence for a novel type of blocking IgG.

Authors:  B Selander; H Käyhty; E Wedege; E Holmström; L Truedsson; C Söderström; A G Sjöholm
Journal:  J Clin Immunol       Date:  2000-03       Impact factor: 8.317

7.  A critical threshold of meningococcal factor H binding protein expression is required for increased breadth of protective antibodies elicited by native outer membrane vesicle vaccines.

Authors:  Oliver Koeberling; Isabel Delany; Dan M Granoff
Journal:  Clin Vaccine Immunol       Date:  2011-03-02

8.  Dramatic decline of serogroup C meningococcal disease incidence in Catalonia (Spain) 24 months after a mass vaccination programme of children and young people.

Authors:  L Salleras; A Domínguez; G Prats; I Parron; P Muñoz
Journal:  J Epidemiol Community Health       Date:  2001-04       Impact factor: 3.710

9.  Immunogenicity of meningococcal polysaccharide ACWY vaccine in primary immunized or revaccinated adults.

Authors:  C Ferlito; R Biselli; M S Cattaruzza; R Teloni; S Mariotti; E Tomao; G Salerno; M S Peragallo; P Lulli; S Caporuscio; A Autore; G Bizzarro; V Germano; M I Biondo; A Picchianti Diamanti; S Salemi; R Nisini; R D'Amelio
Journal:  Clin Exp Immunol       Date:  2018-09-20       Impact factor: 4.330

10.  Immune Responses in U.S. Military Personnel Who Received Meningococcal Conjugate Vaccine (MenACWY) Concomitantly with Other Vaccines Were Higher than in Personnel Who Received MenACWY Alone.

Authors:  Michael P Broderick; Sandra Romero-Steiner; Gowrisankar Rajam; Scott E Johnson; Andrea Milton; Ellie Kim; Lisa J Choi; Jennifer M Radin; Daniel S Schmidt; George M Carlone; Nancy Messonnier; Dennis J Faix
Journal:  Clin Vaccine Immunol       Date:  2016-08-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.